<DOC>
	<DOCNO>NCT02891395</DOCNO>
	<brief_summary>Open label non-randomized multicenter phase 2 trial direct individual benefice</brief_summary>
	<brief_title>Efficacy Safety Nilotinib Patients With Chronic Disease Graft Against Host</brief_title>
	<detailed_description>Induction phase : Imatinib mesylate - start 100 mg/day increase 100 mg/day week maximum tolerable dose 400 mg/day whichever occur first . For responder absence toxicity , treatment maintain one year . Patients , discontinue imatinib mesylate 3 month lack response ( response = stable disease ) , experience progression time , relapse initial response time discontinue toxicity time , go salvage phase . Salvage phase : Nilotinib - start 200 mg/day increase 200 mg/day week maximum tolerable dose 800 mg/day whichever occur first . In absence toxicity , treatment maintain one year .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Induction phase ( IM ) : Patients age ≥18 year 75 year Patients underwent alloSCT hematological disorder Body weight ≥ 40 Kg . Confirmed diagnosis cGVHD resistant least one systemic immunosuppressive therapy . The diagnosis cGHVD base NIH Working Group Consensus ( www.asbmt.org/gvhd/index.htm ) . Grading cGVHD base clinical manifestation include : 1. ocular , oral mucosal symptom ; 2. performance status ; 3. evaluation pulmonary function ; 4. cutaneous evaluation ; 5. evaluation musculoskeletal manifestation ; 6. evaluation liver involvement ; Any source hematopoietic stem cell allow Both myeloablative nonmyeloablative conditioning regimen authorize . Absence contraindication use IM Nilotinib Patient French health care coverage Female patient childbearing potential must initiation study drug agree efficient contraceptive precaution throughout trial 3 month end trial . Signed informed consent . Salvage phase ( Nilotinib ) : Patients enrol first phase fail IM : Patients , discontinue imatinib mesylate 3 month lack response ( response = stable disease ) , experience progression time , relapse initial response time discontinue toxicity time . Patient develop acute GVHD ( whether early `` late onset '' form ) First episode cGVHD Patient receive IM Nilotinib treatment TKI transplant 3 month inclusion study Patient treat TKI GVHD Contraindication IM Nilotinib Neutropenia &lt; 0.5 G/L Uncontrolled systemic infection associate , accord investigator , enhance risk patient 's death first month treatment Severe neurological psychiatric disorder Pregnancy lactation Known uncontrolled arrhythmias symptomatic heart disease leave ventricular ejection fraction &lt; 40 % ( cardiac test clinically indicate ) Recurrence cancer transplant do except presence minimal residual disease PCR Patients secondary malignancy ≤ 2 year prior studyentry except : Basal cell carcinoma skin Squamous cell carcinoma skin Carcinoma situ cervix Carcinoma situ breast Prostate cancer ( Tumor , Node , Metastasis [ TNM ] stage T1a T1b ) Patients emergency situation Patients keep detention Patients unable unwilling comply protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>allogeneic stem cell transplantation</keyword>
	<keyword>imatinib Mesylate</keyword>
	<keyword>Nilotinib</keyword>
</DOC>